Erasca (ERAS) | Financial Analysis & Statements
Erasca Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-32.6M
Net Income
-29.1M
EPS (Diluted)
$-0.10
Balance Sheet Metrics
Total Assets
396.2M
Total Liabilities
71.0M
Shareholders Equity
325.2M
Debt to Equity
0.22
Cash Flow Metrics
Operating Cash Flow
-25.0M
Free Cash Flow
-21.7M
Revenue & Profitability Trend
Erasca Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 92.9M | 115.4M | 103.8M | 112.5M | 73.9M |
| Selling, General & Administrative | 38.6M | 41.7M | 37.7M | 33.0M | 22.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 131.4M | 157.1M | 141.5M | 145.4M | 96.5M |
| Operating Income | -131.4M | -157.1M | -141.5M | -145.4M | -96.5M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 16.6M | 20.1M | 16.7M | 4.9M | 190.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -9.7M | -24.7M | -229.0K | -102.3M | -26.4M |
| Pre-tax Income | -124.5M | -161.6M | -125.0M | -242.8M | -122.8M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -124.5M | -161.6M | -125.0M | -242.8M | -122.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -118.8M | -130.8M | -137.8M | -40.8M | -67.4M |
| EPS (Basic) | - | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
| EPS (Diluted) | - | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
| Basic Shares Outstanding | - | 233817916 | 150184994 | 122024848 | 66290592 |
| Diluted Shares Outstanding | - | 233817916 | 150184994 | 122024848 | 66290592 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Erasca Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 73.8M | 67.7M | 93.1M | 284.2M | 360.5M |
| Short-term Investments | 202.3M | 230.6M | 219.3M | 151.4M | 54.0M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 10.2M | 10.5M | 8.3M | 8.9M | 5.5M |
| Total Current Assets | 286.2M | 308.8M | 320.7M | 444.5M | 420.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.4M | 4.7M | 5.6M | 4.8M | 2.5M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.9M | 3.0M | 4.8M | 5.2M | 3.3M |
| Total Non-Current Assets | 109.9M | 193.7M | 74.6M | 70.4M | 81.4M |
| Total Assets | 396.2M | 502.5M | 395.3M | 514.9M | 501.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 981.0K | 468.0K | 2.0M | 23.0M | 4.7M |
| Short-term Debt | 5.1M | 4.6M | 4.0M | 1.3M | 285.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 464.0K | 1.7M | 2.9M |
| Total Current Liabilities | 28.5M | 31.4M | 26.2M | 48.7M | 26.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 42.1M | 47.3M | 51.9M | 53.8M | 18.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 399.0K | 362.0K | 566.0K | 573.0K | 158.0K |
| Total Non-Current Liabilities | 42.5M | 47.6M | 52.5M | 54.4M | 18.7M |
| Total Liabilities | 71.0M | 79.0M | 78.6M | 103.1M | 44.9M |
| Equity | |||||
| Common Stock | 28.0K | 28.0K | 15.0K | 15.0K | 12.0K |
| Retained Earnings | -892.2M | -767.7M | -606.0M | -481.0M | -238.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 325.2M | 423.5M | 316.7M | 411.9M | 456.5M |
| Key Metrics | |||||
| Total Debt | 47.1M | 51.9M | 55.9M | 55.1M | 18.8M |
| Working Capital | 257.7M | 277.4M | 294.5M | 395.8M | 393.8M |
Balance Sheet Composition
Erasca Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -124.5M | -161.6M | -125.0M | -242.8M | -122.8M |
| Depreciation & Amortization | 3.1M | 3.8M | 3.7M | 2.6M | 829.0K |
| Stock-Based Compensation | 24.9M | 27.0M | 26.2M | 20.1M | 8.3M |
| Working Capital Changes | -1.3M | -2.3M | 2.2M | 14.4M | 2.6M |
| Operating Cash Flow | -88.4M | -110.6M | -92.9M | -103.7M | -83.2M |
| Investing Activities | |||||
| Capital Expenditures | -128.0K | -60.0K | -1.8M | -14.6M | -11.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -151.0M | -403.4M | -314.4M | -134.3M | -105.8M |
| Investment Sales | 261.0M | 269.3M | 244.9M | 79.8M | 60.1M |
| Investing Cash Flow | 109.9M | -134.1M | -71.2M | -69.1M | -56.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 239.1M | 0 | 95.3M | 436.9M |
| Free Cash Flow | -105.1M | -132.0M | -123.0M | -119.8M | -98.5M |
| Net Change in Cash | 21.5M | -5.7M | -164.1M | -77.5M | 296.8M |
Cash Flow Trend
Erasca Key Financial Ratios
Valuation Ratios
Forward P/E
-41.49
Price to Book
19.64
PEG Ratio
-41.49
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-33.27%
Return on Assets
-18.28%
Financial Health
Current Ratio
10.04
Debt to Equity
14.50
Beta
1.05
Per Share Data
EPS (TTM)
$-0.44
Book Value per Share
$1.14
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ERAS | 7.0B | - | 19.64 | -33.27% | 0.00% | 14.50 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






